Medication Guide App

Label Changes for:

Ditropan (oxybutynin chloride) Tablets and Syrup

February 2008

Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

Sections Modified

PRECAUTIONS

  • Central Nervous System Effects
  • Oxybutynin is associated with anticholinergic central nervous system (CNS) effects. A variety of CNS anticholingeric effects have been reported...
  • Ditropan should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.

ADVERSE REACTIONS (see highlighted section)

  • The following adverse events were reported by 1 to <5% of patients using Ditropan (5 - 20 mg/day):
    • Infections and Infestations
    • Metabolism and Nutrition Disorders
    • Psychiatric Disorders
    • Nervous System Disorders
    • Eye Disorders
    • Cardiac Disorders
    • Vascular Disorders
    • Respiratory, Thoracic and Mediastinal Disorders
    • Gastrointestinal Disorders
    • Skin and Subcutaneous Tissue Disorders
    • Musculoskeletal and Connective Tissue Disorders
    • Renal and Urinary Disorders
    • General Disorders and Administration Site Conditions
    • Investigations
    • Injury, Poisoning, and Procedural Complications
  • Postmarketing Surveillance
    • Psychiatric Disorders
    • Nervous System Disorders
    • Eye Disorders
    • Cardiac Disorders
    • Gastrointestinal Disorders
    • Skin and Subcutaneous Tissue Disorders
    • Renal and Urinary Disorders
    • Reproductive System and Breast Disorders
Hide
(web2)